Jointown Pharmaceutical Group Croissance future

Future contrôle des critères 1/6

Jointown Pharmaceutical Group devrait augmenter ses bénéfices et son chiffre d'affaires de 17.1% et de 8% par an respectivement. Le BPA devrait croître de de 15% par an. Le rendement des capitaux propres devrait être 10.4% dans 3 ans.

Informations clés

17.1%

Taux de croissance des bénéfices

15.0%

Taux de croissance du BPA

Healthcare croissance des bénéfices	23.0%
Taux de croissance des recettes	8.0%
Rendement futur des capitaux propres	10.4%
Couverture par les analystes	Low
Dernière mise à jour	08 Nov 2024

Mises à jour récentes de la croissance future

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Aug 29

Recent updates

We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt

Nov 17

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Aug 29

Earnings Working Against Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Share Price

Aug 26

These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well

Aug 01

Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward

Jun 07

Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors

May 21

Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)

Apr 05

Prévisions de croissance des bénéfices et des revenus

SHSE:600998 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	179,870	3,082	N/A	4,296	4
12/31/2025	167,170	2,721	N/A	2,254	5
12/31/2024	156,373	2,353	N/A	4,515	4
9/30/2024	149,205	2,047	317	1,291	N/A
6/30/2024	147,953	2,039	82	1,029	N/A
3/31/2024	148,519	2,151	3,155	4,116	N/A
12/31/2023	150,140	2,174	3,699	4,748	N/A
9/30/2023	151,842	2,170	5,217	6,257	N/A
6/30/2023	151,797	2,159	5,409	6,559	N/A
3/31/2023	147,366	2,194	2,395	3,611	N/A
12/31/2022	140,424	2,085	2,743	3,986	N/A
9/30/2022	133,260	1,782	3,638	4,886	N/A
6/30/2022	128,411	1,545	1,345	2,656	N/A
3/31/2022	124,929	2,141	1,862	3,234	N/A
12/31/2021	122,407	2,448	2,073	3,459	N/A
9/30/2021	122,634	3,339	282	1,907	N/A
6/30/2021	121,491	3,988	3,113	4,802	N/A
3/31/2021	116,315	3,258	2,009	3,574	N/A
12/31/2020	110,860	3,075	1,987	3,444	N/A
9/30/2020	106,438	2,849	2,930	4,117	N/A
6/30/2020	102,417	2,242	2,025	3,152	N/A
3/31/2020	102,007	1,976	2,349	3,480	N/A
12/31/2019	99,497	1,727	1,576	2,768	N/A
9/30/2019	96,769	1,588	1,479	2,737	N/A
6/30/2019	93,116	1,547	1,882	3,123	N/A
3/31/2019	89,589	1,446	583	1,833	N/A
12/31/2018	87,136	1,341	-593	1,222	N/A
9/30/2018	83,230	1,262	-1,949	-231	N/A
6/30/2018	80,163	1,189	N/A	-2,213	N/A
3/31/2018	77,339	1,481	N/A	-2,221	N/A
12/31/2017	73,943	1,446	N/A	-1,012	N/A
9/30/2017	70,783	1,374	N/A	-2,586	N/A
6/30/2017	67,999	1,360	N/A	-198	N/A
3/31/2017	64,925	921	N/A	1,382	N/A
12/31/2016	61,557	877	N/A	431	N/A
9/30/2016	58,367	777	N/A	1,748	N/A
6/30/2016	55,482	754	N/A	193	N/A
3/31/2016	53,091	718	N/A	-783	N/A
12/31/2015	49,589	695	N/A	436	N/A
9/30/2015	46,895	640	N/A	-1,088	N/A
6/30/2015	45,049	602	N/A	-1,287	N/A
3/31/2015	43,171	566	N/A	-312	N/A
12/31/2014	41,068	561	N/A	-172	N/A
9/30/2014	39,273	533	N/A	-450	N/A
6/30/2014	37,189	509	N/A	-702	N/A
3/31/2014	35,150	493	N/A	-1,230	N/A
12/31/2013	33,438	478	N/A	138	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 600998 ( 17.1% par an) est supérieure au taux d'épargne ( 2.8% ).

Bénéfices vs marché: Les bénéfices de 600998 ( 17.1% par an) devraient croître plus lentement que le marché CN ( 26.2% par an).

Croissance élevée des bénéfices: Les bénéfices de 600998 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 600998 ( 8% par an) devrait croître plus lentement que le marché de CN ( 13.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 600998 ( 8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 600998 devrait être faible dans 3 ans ( 10.4 %).

Jointown Pharmaceutical Group Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 14% to CN¥6.41

Consensus EPS estimates fall by 13%

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Consensus EPS estimates fall by 11%

Price target increased by 23% to CN¥9.48

Price target decreased by 10% to CN¥7.70

Recent updates

We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt

Price target decreased by 14% to CN¥6.41

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Jointown Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 17%

Consensus EPS estimates fall by 13%

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Earnings Working Against Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Share Price

These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well

Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 300 million worth of its shares.

Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward

Investor sentiment deteriorates as stock falls 23%

Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors

Consensus EPS estimates fall by 11%

Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 24, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 23% to CN¥9.48

Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)

Jointown Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 18%

Jointown Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Price target decreased by 10% to CN¥7.70

Third quarter 2023 earnings released: EPS: CN¥1.16 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 30%

Price target increased by 15% to CN¥12.04

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.29 in 2Q 2022)

Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023

Price target increased by 7.4% to CN¥15.62

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.23 in 1Q 2022)

Price target increased by 8.5% to CN¥14.54

Less than half of directors are independent

Consensus forecasts updated

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.12 in 3Q 2021)

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.77 in 2Q 2021)

Consensus EPS estimates fall by 48%

Price target decreased to CN¥13.40

Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 600 million worth of its shares.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.48 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.37 in 2Q 2020)

Price target decreased to CN¥19.00

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.32 in 1Q 2020)

New 90-day low: CN¥17.10

Price target raised to CN¥20.35

New 90-day high: CN¥18.60

Analysts update estimates

Third quarter earnings released

Annual earnings released: Earnings beat expectations

Jointown Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million.

New 90-day low - CN¥17.39

Earnings released

New 90-day high - CN¥20.19

Jointown Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance